Načítá se...
Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine
We previously reported that topical imiquimod can improve the immunogenicity of the influenza vaccine. This study investigated another FDA-approved drug, miltefosine (MTF), as a vaccine adjuvant. Mice immunized with an influenza vaccine with or without MTF adjuvant were challenged by a lethal dose o...
Uloženo v:
| Vydáno v: | Vaccines (Basel) |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7768360/ https://ncbi.nlm.nih.gov/pubmed/33322574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines8040754 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|